An interventional study of Kinetics and Absolute in Infection and Sepsis, sponsored by Semmelweis University. Recruiting at 2 sites in Hungary. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Semmelweis University · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Sepsis with a site in Hungary — 4 open to participants now, 4 under way, none of them phase 3. Sepsis · Hungary.
Among the 22 studies in Sepsis with a site in Hungary, this one is the 6th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2025, is one of 2 with no phase, and was the 19th registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →4 of the 22 studies in Sepsis with a site in Hungary are open now. Recruiting first, the newest first:
Semmelweis University · Sites in Hungary
Ages 0 hrs–17 yrs
AstraZeneca · Sites in Hungary, United States, Argentina and 11 more countries
Ages 18–80
Semmelweis University · Sites in Hungary
Ages 18–80
A study can be open while its sites in Hungary have not opened yet or have stopped. Only those recruiting at a site in Hungary →
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 2 · Phase 4 3
First in 2001; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 102 across 1,169 interventional studies indexed under Sepsis.
Median enrollment 130 across the 16 interventional studies, 213 across the 6 observational. Of the 16 that completed or were terminated, 5 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 22 have an industry lead sponsor. The 10 most frequent:
Semmelweis University is the lead sponsor of 140 studies on the registry; 55 are open to participants now.
Semmelweis University has 3 studies filed under Sepsis — fewer than ten, so there is no comparison to draw.
1 of the studies in Sepsis with a site in Hungary that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07215702AstraZenecaA Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. | 2027-02-11 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Sepsis with a site in Hungary, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims to compare the efficacy and safety of an absolute procalcitonin (PCT) value-guided antibiotic initiation protocol and a protocol using the kinetics of PCT (the difference between the actual and the previous day value) in hemodynamically stable critically ill patients with suspected new-onset infection on admission or during ICU stay.
The main question it aims to answer:
Appropriate antibiotic (AB) therapy is still a big challenge in intensive care units today. More than 50% of our patients are considered potentially infected, and infection alone can double mortality; however, infection is later confirmed in less than 60% of patients admitted with the initial diagnosis of sepsis. According to previous studies, at least every fifth patient in intensive care units receives unnecessary antibiotics (ABs), leading to the well-known adverse effects of ABs without any benefit. The emergence of AB resistance has been associated with 700,000 avoidable deaths in 2014, and WHO estimates that it will contribute to the death of 10 million people by 2050.
Procalcitonin (PCT) is one of the most studied inflammatory biomarkers. Several randomized controlled trials (RCTs) and their meta-analyses concluded that PCT-guided antibiotic treatment could reduce the length of AB therapy without adverse effects; moreover, it may be associated with reduced 28-day mortality, which was also confirmed by our study in 2023. Accordingly, the current sepsis guideline recommends the combined evaluation of the clinical picture and PCT when stopping AB therapy; however, it contains a weak recommendation against using PCT when starting the treatment. The latter proposition is based on three studies with a significant number of surgical patients (around 40%) in two of them, in whom the applied PCT cut-off (0.5-1 ng/ml) presumably was too low, supported by several previous studies. Therefore, the overuse of ABs was more or less hardcoded into the protocol.
Kinetics of an inflammatory biomarker can carry much more information about the host response to infection instead of a single value. In a prospective observational study by Trasy et al., early PCT kinetics (PCT change between the day of suspected infection and the previous 24 hours) predicted infection, while PCT did not change in the group of patients in whom the infection was later ruled out. Tsangaris and his colleagues measured PCT daily in critically ill patients. The investigators noted a two-fold increase in PCT levels between the day of fever onset and the previous day if the patients had an infection, while there was no difference in the PCT values if the participants had no infection.
Based on these findings, the investigators created a protocol to reduce the number of unnecessary antibiotic therapies using the kinetics of PCT.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
This study's planned enrollment of 250 is above the median of 102 across 1,169 interventional studies indexed under Sepsis.
Browse Sepsis studies →Semmelweis University is the lead sponsor of 140 studies on the registry; 55 are open to participants now.
Compared within Sepsis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the case of a suspected new-onset infection, the treating physician starts antibiotic therapy according to a predefined protocol depending on the kinetics of PCT.
Other: Kinetics
In the case of a new-onset infection, starting ABs is recommended depending on the actual absolute value of PCT.
Other: Absolute
Initiation of the AB therapy is recommended for the clinician if PCT ≥ 0.5 ng/ml and PCT elevation ≥100% from the previous day's value.
According to the antibiotic protocol, starting ABs is recommended if PCT ≥ 0.5 ng/ml.
Rate of unnecessary antibiotic therapy
The number of unjustified antibiotic therapies divided by the number of all therapies.
Time frame: From date of enrollment until 72 hours.
Organ-support free days
Number of days alive without life support - mechanical ventilation, vasoactive therapy and renal replacement therapy.
Time frame: From date of enrollment until the date of disharge of the patient from the ICU or the date of patient's death from any cause, whichever came first, assessed up to 6 months.
Lenght of stay at the intensive care unit
Number of days the patient stays at ICU
Time frame: From date of enrollment until the date of discharge of patient from the ICU or the date of patient's death from any cause, whichever came first, assessed up to 6 months.
Length of stay in hospital
Number of days the patient stays in the hospital
Time frame: From date of enrollment until the date of hospital discharge of the patient or the date of patient's death from any cause, whichever came first, assessed up to 6 months.
Duration of mechanical ventilation
Duration of mechanical ventilation in days
Time frame: From date of enrollment until date of ICU discharge of the patient or date of patient's death from any cause, whichever came first, asessed up to 6 months.
Duration of renal replacement therapy
Duration of renal replacement therapy in days
Time frame: From date of enrollment until date of hospital discharge of the patient or date of patient's death from any cause, whichever came first, assessed up to 6 months.
Duration of catecholamine circulatory support
Duration of catecholamine circulatory support in days
Time frame: From date of enrollment until date of ICU discharge of the patient or date of patient's death from any cause, whichever came first, assessed up to 6 months.
ICU mortality
The number of patients died during ICU stay devided by the number of patients enrolled.
Time frame: From date of enrollment until the date of ICU discharge of the patient, assessed up to 6 months.
28-day mortality
The number of patients died divided by the number of patients enrolled.
Time frame: From date of enrollment until day 28.
In-hospital mortality
The number of patients died devided by the number of patients enrolled.
Time frame: From date of enrollment until hospital discharge of the patient, assessed up to 6 months.
Number of Multidrug-resistant Organism caused infections
Number of diagnosed infections caused by bacteria that are resistant to one or more classes of antimicrobial agents.
Time frame: From date of enrollment until the date of hospital discharge of the patient or the patient's death from any cause, whichever came first, assessed up to 6 months.
Number of Clostridioides difficile infections
Number of verified Clostridioides difficile infections
Time frame: From date of enrollment until the date of hospital discharge of the patient or the patient's death from any cause, whichever came first, assessed up to 6 months.
Plan to share: Yes — All data obtained through the study may be provided to researchers with an interest in optimizing antibiotic therapy of critically ill patients. Data and samples will be coded if shared with no protected health information included. Zsolt Molnár will receive invitations/requests to share individual participant data, and will consider if the request: 1) explicitly serves public benefit, 2) complies with local ethical and data security regulations of the requesting and providing institutions, 3) lays out the existing or planned legal and technical infrastructure for data transfer, 4) provides a publicly available protocol for planned statistical analyses.
Started Nov 2025 (actual). Primary completion is estimated for Dec 2027, 25 months after the start.
Of 303 non-industry interventional studies with no phase under Sepsis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 25 months is close to that.
Counting every sponsor, half of 326 studies reached it within 22 months; a quarter within 11 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.